Dowling & Yahnke’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $6.66M | Sell |
56,977
-2,030
| -3% | -$252K | 0.31% | 80 |
|
|
2022
Q2 | $6.94M | Sell |
59,007
-3,227
| -5% | -$383K | 0.33% | 78 |
|
|
2022
Q1 | $8.11M | Sell |
62,234
-4,626
| -7% | -$603K | 0.35% | 79 |
|
|
2021
Q4 | $10.2M | Sell |
66,860
-5,812
| -8% | -$900K | 0.49% | 61 |
|
|
2021
Q3 | $11.8M | Sell |
72,672
-4,124
| -5% | -$694K | 0.65% | 37 |
|
|
2021
Q2 | $12.6M | Sell |
76,796
-3,590
| -4% | -$553K | 0.72% | 32 |
|
|
2021
Q1 | $12.1M | Sell |
80,386
-1,563
| -2% | -$248K | 0.83% | 28 |
|
|
2020
Q4 | $12.4M | Sell |
81,949
-547
| -0.7% | -$78.2K | 0.88% | 26 |
|
|
2020
Q3 | $11.2M | Sell |
82,496
-379
| -0.5% | -$51.4K | 0.9% | 25 |
|
|
2020
Q2 | $11.3M | Sell |
82,875
-687
| -0.8% | -$87.6K | 0.95% | 24 |
|
|
2020
Q1 | $9M | Sell |
83,562
-3,526
| -4% | -$406K | 0.87% | 27 |
|
|
2019
Q4 | $10.5M | Sell |
87,088
-1,440
| -2% | -$161K | 0.81% | 29 |
|
|
2019
Q3 | $8.81M | Buy |
88,528
+1,466
| +2% | +$153K | 0.73% | 34 |
|
|
2019
Q2 | $9.5M | Sell |
87,062
-745
| -0.8% | -$79.2K | 0.79% | 30 |
|
|
2019
Q1 | $9.82M | Sell |
87,807
-1,521
| -2% | -$167K | 0.94% | 27 |
|
|
2018
Q4 | $9.75M | Sell |
89,328
-369
| -0.4% | -$39.2K | 1.01% | 24 |
|
|
2018
Q3 | $10.9M | Sell |
89,697
-1,182
| -1% | -$139K | 0.95% | 22 |
|
|
2018
Q2 | $9.98M | Sell |
90,879
-771
| -0.8% | -$82.5K | 0.93% | 23 |
|
|
2018
Q1 | $9.78M | Sell |
91,650
-1,301
| -1% | -$144K | 0.92% | 22 |
|
|
2017
Q4 | $9.92M | Buy |
92,951
+248
| +0.3% | +$26.5K | 0.9% | 23 |
|
|
2017
Q3 | $10.3M | Sell |
92,703
-528
| -0.6% | -$56.4K | 1.05% | 15 |
|
|
2017
Q2 | $9.64M | Sell |
93,231
-795
| -0.8% | -$78.3K | 1.02% | 17 |
|
|
2017
Q1 | $9.19M | Buy |
94,026
+153
| +0.2% | +$14.6K | 0.98% | 21 |
|
|
2016
Q4 | $8.3M | Sell |
93,873
-1,323
| -1% | -$120K | 0.93% | 24 |
|
|
2016
Q3 | $9.19M | Sell |
95,196
-843
| -0.9% | -$80.2K | 1.07% | 17 |
|
|
2016
Q2 | $8.24M | Buy |
96,039
+2,397
| +3% | +$215K | 0.99% | 22 |
|
|
2016
Q1 | $8.14M | Buy |
93,642
+390
| +0.4% | +$34.9K | 1.01% | 22 |
|
|
2015
Q4 | $10.5M | Sell |
93,252
-1,677
| -2% | -$182K | 1.32% | 6 |
|
|
2015
Q3 | $9.6M | Buy |
94,929
+210
| +0.2% | +$25.2K | 1.31% | 9 |
|
|
2015
Q2 | $11.6M | Sell |
94,719
-1,572
| -2% | -$188K | 1.47% | 6 |
|
|
2015
Q1 | $11M | Sell |
96,291
-1,071
| -1% | -$118K | 1.38% | 9 |
|
|
2014
Q4 | $9.85M | Sell |
97,362
-1,950
| -2% | -$190K | 1.23% | 11 |
|
|
2014
Q3 | $9.06M | Sell |
99,312
-2,013
| -2% | -$177K | 1.19% | 12 |
|
|
2014
Q2 | $8.68M | Sell |
101,325
-2,268
| -2% | -$179K | 1.12% | 13 |
|
|
2014
Q1 | $8.16M | Sell |
103,593
-1,371
| -1% | -$114K | 1.08% | 13 |
|
|
2013
Q4 | $7.94M | Sell |
104,964
-81
| -0.1% | -$5.75K | 1.12% | 13 |
|
|
2013
Q3 | $7.34M | Sell |
105,045
-447
| -0.4% | -$29.3K | 1.15% | 14 |
|
|
2013
Q2 | $6.11M | Buy |
+105,492
| New | +$6.1M | 1.02% | 18 |
|
Other funds holding IBB
CB
Dowling & Yahnke's IBB Position: Q3 2022 in Review
Dowling & Yahnke reduced its iShares Biotechnology ETF (IBB) stake by 3.4% in Q3 2022, selling an estimated $252K and leaving 56,977 shares worth $6.66M. The position accounts for 0.31% of the portfolio, ranked #80.
Dowling & Yahnke first reported a position in IBB in Q2 2013 and has held it in 38 quarters since. The position peaked at $12.6M in Q2 2021. 830 funds tracked by Wall St. Rank hold IBB as of Q3 2022.
- Dowling & Yahnke held 56,977 shares of iShares Biotechnology ETF worth $6.66M as of Q3 2022.
- Dowling & Yahnke sold 2,030 iShares Biotechnology ETF shares in Q3 2022, an estimated $252K.
- iShares Biotechnology ETF made up 0.31% of Dowling & Yahnke's portfolio in Q3 2022, its #80 holding.
- Dowling & Yahnke first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's iShares Biotechnology ETF position peaked at $12.6M in Q2 2021.
- 830 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.